Isolde Butler, MD, MPH; Raphael Landovitz, MD, MSc; Daniel Richardson FRCP, FAChSHM
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is in collaboration with HealthHIV.
This activity is supported by an educational grant from Gilead Sciences, Inc.
The educational design of this activity addresses the needs of primary care providers (PCPs), nurse practitioners (NPs), and physician assistants (PAs), invovled in HIV prevention services for their patients.
The third activity in this series provides the tools necessary for clinicians “to get to the finish line” and implement PrEP in their clinics; materials will include updated 2021 CDC guidelines, guidelines from Europe and the United Kingdom, efficacy and safety data for the available PrEP agents, as well as a review of how to initiate medication and the need for patient monitoring and follow-up.
After completing this activity, the participant should be better able to:
- Describe characteristics of current and emerging PrEP options, including dosage forms, route of administration, and frequency
- Align clinical practices with updated guideline-based recommendations for PrEP initiation and monitoring
- Employ shared decision-making strategies to individualize PrEP management
Isolde Butler, MD, MPH
Physician Site Director
New Orleans, Louisiana
Raphael Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
Associate Director, Center for Clinical AIDS Research & Education
University of California, Los Angeles
Los Angeles, California
Daniel Richardson, FRCP, FAChSHM
Consultant and Clinical Reader in Sexual Health & HIV Medicine
University Hospitals Sussex NHS Foundation Trust
Brighton & Sussex Medical School
Brighton, United Kingdom
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Continuing Medical Education
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hours (which includes 0.1 hours of pharmacology).
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 70% or better on the posttest, and complete the program evaluation.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at firstname.lastname@example.org.
Disclosure of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global . All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Isolde Butler, MD, MPH: Nothing to disclose
Raphael Landovitz, MD, MSc: Consulting Fees: Gilead Sciences, Inc., Merck Inc. Honoraria: Cepheid, Janssen
Daniel Richardson, FRCP, FAChSHM: Nothing to disclose
The planners and managers have the following relevant financial relationships with ineligible companies.
Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose
Jim Kappler, PhD: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)